High prevalence of influenza and flu has created a demand for Tamiflu (Oseltamivir Phosphate). Thus, companies are entering into strategic deals to gain rights for over-the-counter (OTC) distribution of the medication. For instance, in July 2019, leading French multinational pharmaceutical company Sanofi entered into an agreement with Roche-a Swiss multinational healthcare company, to gain rights for over-the-counter distribution of Tamiflu in the U.S. Such deals are boosting the growth of the Tamiflu (Oseltamivir Phosphate) market, which is projected to reach a revenue of ~US$ 940 Mn by the end of 2027.
Companies in the Tamiflu (Oseltamivir Phosphate) market are increasing their production capabilities to manufacture novel medication for the prevention and treatment of life-threatening influenza diseases and other flu. They are increasing efficacy in FDA negotiations for marketing and scientific engagement associated with Tamiflu to gain credibility in the global market landscape.
To know the scope of our report Get a Sample on Tamiflu (Oseltamivir Phosphate) Market
The Tamiflu (Oseltamivir Phosphate) market is witnessing change, since healthcare companies are pervasively switching toward OTC distribution, especially in the U.S. Since the U.S. being one of the rapidly growing economies of North America, the latter is expected to reach the second-highest revenue in the Tamiflu (Oseltamivir Phosphate) market by the end of 2027. Hence, companies in the U.S. are capitalizing on the trend of OTC switch. Looking at leading market players, even emerging players are aiming at the OTC switch and aiming toward strategic transactions to introduce innovations in Tamiflu (Oseltamivir Phosphate).
Companies in the market for Tamiflu (Oseltamivir Phosphate) are targeting the U.S., since the region is one of the largest OTC market worldwide. The OTC switch is supporting the global cough and cold strategy of market players by expanding into flu with a sustainable point of difference in the market. Tamiflu is being highly publicized in support of public health, since novel medication offers safe and efficacious treatment for flu and influenza.
Health institutions such as the Centers for Disease Control and Prevention, U.S., recommend that newly born infants should receive flu vaccine at regular periodic intervals. However, frequent replication and mutation of the influenza virus has contributed toward high prevalence of the infection. This phenomena has fueled the demand for Tamiflu (Oseltamivir Phosphate) medication. However, substitute antiviral drugs such as Baloxavir marboxil and Peramivir pose as a threat to the sales of Tamiflu (Oseltamivir Phosphate). Easy availability of substitute drugs explains the steep downward Y-o-Y growth of the Tamiflu (Oseltamivir Phosphate) market. Hence, manufacturers are entering into strategic deals for OTC distribution and increasing production capabilities in dosage forms of Tamiflu.
Get a glimpse of the in-depth analysis through our Report Brochure
Tamiflu capsules dictate the highest revenue as compared to suspension dosages in the Tamiflu (Oseltamivir Phosphate) market and the capsule dosage form segment is predicted for exponential growth in the coming years. On the other hand, companies are increasing the availability of Tamiflu in the suspension dosage form for patients with end-stage renal disease (ESRD) and those on continuous ambulatory peritoneal dialysis (CAPD).
It has been found that Tamiflu (Oseltamivir Phosphate) is an efficacious antiviral drug for the treatment of flu and influenza, especially among the geriatric patients. Companies in the Tamiflu (Oseltamivir Phosphate) market are increasing their focus in Europe, this market in the region is expected for aggressive growth during the forecast period. The Lancet- a European Commission-funded study revealed that Tamiflu (Oseltamivir Phosphate) is recommended by public health agencies for the prevention and treatment of seasonal and pandemic influenza outbreaks.
Ongoing research studies that are publicly funded in several European countries are generating incremental opportunities for companies in the Tamiflu (Oseltamivir Phosphate) market, since companies are gaining important insights through these studies. Healthcare providers in Europe are also recommending Tamiflu for young and old patients with flu-like illnesses.
Analysts’ Viewpoint
Healthcare companies in the Tamiflu (Oseltamivir Phosphate) market are exploring opportunities in Asia Pacific, since government institutions in the region are increasing their efforts to improve the healthcare infrastructure. On the other hand, companies are maximizing their production capabilities to develop generic drugs and increasing efforts to strengthen their online distribution channels.
Tamiflu is efficacious in the treatment of ESRD and for patients who rely on CAPD. However, side effects of Tamiflu, such as diarrhea, and introduction of substitute drugs such as XofluzaTM (baloxavir marboxil) by Roche, are likely to slow down market growth. Hence, companies should increase their efficacy in conducting extensive research studies catering to the development of drugs targeting children and infants.
Tamiflu (Oseltamivir Phosphate) Market – Segmentation
TMR’s study on the global Tamiflu (Oseltamivir Phosphate) market includes information divided into five sections-drug type, dosage form, indication, distribution channel, and by region. Changing industry trends and other crucial market dynamics associated with these sections of the global Tamiflu (Oseltamivir Phosphate) market have been discussed in detail.
|
Drug Type |
Branded Generic |
|
Dosage Form |
Capsule Suspension |
|
Indication |
Influenza A Influenza B Others |
|
Distribution Channel |
Hospital Pharmacies Retail Pharmacies Online Pharmacies Others |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Tamiflu (oseltamivir phosphate) market is projected to reach a revenue of ~US$ 940 Mn by the end of 2027
Tamiflu (oseltamivir phosphate) market is expected to expand at a CAGR of -4% during the forecast period from 2019 to 2027
Tamiflu (oseltamivir phosphate) market is driven by increase in prevalence of influenza across the globe
North America accounted for a major share of the global tamiflu (oseltamivir phosphate) market
Key players in the tamiflu (oseltamivir phosphate) market include F.Hoffmann-La Roche Ltd., NATCO Pharma Limited, Tea Pharmaceutical Industries Ltd., LUPIN Limited, Amneal Pharmaceuticals LLC
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Tamiflu (Oseltamivir Phosphate) Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. 5.1.Influenza Flu Prevalence globally
5.2. 5.2.Key Mergers, Acquisition, and Strategic Partnerships
5.3. 5.3.Top Dugs Sales Analysis of Oseltamivir Phosphate brand
6. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2027
6.3.1. Branded
6.3.2. Generic
6.4. Market Attractiveness, by Drug Type
7. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Dosage Form
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Dosage Form, 2017–2027
7.3.1. Capsule
7.3.2. Suspension
7.4. Market Attractiveness, by Dosage Form
8. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Indication, 2017–2027
8.3.1. Influenza A
8.3.2. Influenza B
8.3.3. Others
8.4. Market Attractiveness, by Indication
9. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.3.4. Others
9.4. Market Attractiveness, by Distribution Channel
10. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region
11. North America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2027
11.2.1. Branded
11.2.2. Generic
11.3. Market Value Forecast, by Dosage Form, 2017–2027
11.3.1. Capsule
11.3.2. Suspension
11.4. Market Value Forecast, by Indication, 2017–2027
11.4.1. Influenza A
11.4.2. Influenza B
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2027
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.5.4. Others
11.6. Market Value Forecast, by Country, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Dosage Form
11.7.3. By Indication
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2027
12.2.1. Branded
12.2.2. Generic
12.3. Market Value Forecast, by Dosage Form, 2017–2027
12.3.1. Capsule
12.3.2. Suspension
12.4. Market Value Forecast, by Indication, 2017–2027
12.4.1. Influenza A
12.4.2. Influenza B
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2027
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Dosage Form
12.7.3. By Indication
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2027
13.2.1. Branded
13.2.2. Generic
13.3. Market Value Forecast, by Dosage Form, 2017–2027
13.3.1. Capsule
13.3.2. Suspension
13.4. Market Value Forecast, by Indication, 2017–2027
13.4.1. Influenza A
13.4.2. Influenza B
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2027
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2027
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Dosage Form
13.7.3. By Indication
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017–2027
14.2.1. Branded
14.2.2. Generic
14.3. Market Value Forecast, by Dosage Form, 2017–2027
14.3.1. Capsule
14.3.2. Suspension
14.4. Market Value Forecast, by Indication, 2017–2027
14.4.1. Influenza A
14.4.2. Influenza B
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2027
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Dosage Form
14.7.3. By Indication
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2017–2027
15.2.1. Branded
15.2.2. Generic
15.3. Market Value Forecast, by Dosage Form, 2017–2027
15.3.1. Capsule
15.3.2. Suspension
15.4. Market Value Forecast, by Indication, 2017–2027
15.4.1. Influenza A
15.4.2. Influenza B
15.4.3. Others
15.5. Market Value Forecast, by Distribution Channel, 2017–2027
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.5.4. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Type
15.7.2. By Dosage Form
15.7.3. By Indication
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis, by Company (2016)
16.3. Company Profiles
16.3.1. F.Hoffmann-La Roche Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. NATCO Pharma Limited
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. Teva Pharmaceutical Industries Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. LUPIN Limited
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Amneal pharmaceuticals LLC
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Zydus Cadila
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Sun Pharmaceutical Industries Ltd.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Alembic Pharmaceuticals Limited
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. Mylan N.V.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Company Financials
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. Hetero Group
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Company Financials
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
List of Tables
Table 01: Key Mergers, Acquisition, and Strategic Partnerships
Table 02: Top Drugs Sales (US$ Mn) Analysis of Oseltamivir Phosphate brand (Tamiflu) by F.Hoffmann-La Roche Ltd.
Table 03: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 04: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 05: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 06: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 07: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 09: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 10: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 11: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 12: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 13: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 15: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 16: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 17: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 18: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 20: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 21: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 22: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 23: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 24: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 25: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 26: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 27: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 28: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 29: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 30: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 31: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 32: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
List of Figures
Figure 01: Global Tamiflu (Oseltamivir Phosphate) Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 02: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, 2017–2027
Figure 03: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type (2018)
Figure 04: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form (2018)
Figure 05: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication (2018)
Figure 06: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel (2018)
Figure 07: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Region (2018)
Figure 08: Global Tamiflu (Oseltamivir Phosphate) Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 09: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Branded, 2017-2027
Figure 10: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Generic, 2017-2027
Figure 11: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness Analysis, by Drug Type, 2019-2027
Figure 12: Global Tamiflu (Oseltamivir Phosphate) Market Value Share Analysis, by Dosage Form, 2018 and 2027
Figure 13: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Capsule, 2017–2027
Figure 14: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Suspension, 2017–2027
Figure 15: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027
Figure 16: Global Tamiflu (Oseltamivir Phosphate) Market Value Share Analysis, by Indication, 2018 and 2027
Figure 17: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Influenza A, 2017–2027
Figure 18: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Influenza B, 2017–2027
Figure 19: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 20: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027
Figure 21: Global Tamiflu (Oseltamivir Phosphate) Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 22: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 23: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 24: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027
Figure 25: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 26: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 27: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Region, 2018 and 2027
Figure 28: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness Analysis, by Region, 2019–2027
Figure 29: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 30: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country, 2018 and 2027
Figure 31: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country, 2019–2027
Figure 32: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027
Figure 33: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027
Figure 34: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027
Figure 35: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027
Figure 36: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027
Figure 37: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027
Figure 38: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027
Figure 39: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027
Figure 40: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 41: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 42: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 43: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027
Figure 44: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027
Figure 45: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027
Figure 46: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027
Figure 47: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027
Figure 48: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027
Figure 49: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027
Figure 50: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027
Figure 51: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 52: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 53: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 54: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027
Figure 55: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027
Figure 56: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027
Figure 57: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027
Figure 58: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027
Figure 59: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027
Figure 60: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027
Figure 61: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027
Figure 62: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 63: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 64: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 65: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027
Figure 66: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027
Figure 67: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027
Figure 68: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027
Figure 69: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027
Figure 70: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027
Figure 71: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027
Figure 72: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027
Figure 73: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 74: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 75: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 76: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027
Figure 77: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027
Figure 78: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027
Figure 79: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027
Figure 80: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027
Figure 81: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027
Figure 82: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027
Figure 83: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027
Figure 84: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Tamiflu (Oseltamivir Phosphate) Market
*86 figures and 60 tables includes